Isolation and evaluation of commensal lactic acid bacteria effectiveness and a probiotics beverage on inflammatory and microbiological parameters associated with ulcerative colitis

• Grant number: 14/15129-1
• Support Opportunities: Regular Research Grants
• Start date: March 01, 2015
• End date: August 31, 2017
• Field of knowledge: Agronomical Sciences - Food Science and Technology - Food Science
• Principal Investigator: Daniela Cardoso Umbelino Cavallini
• Grantee: Daniela Cardoso Umbelino Cavallini
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated researchers: Alexandra Ivo de Medeiros ; Bruce A. Vallance ; Elizeu Antonio Rossi ; Luis Caetano Martha Antunes ; Luis Carlos Spolidorio ; Raquel Bedani Salvio

Abstract

The use of certain lactic acid bacteria has been considered as a possible and promising therapeutic approach on reducing the risk of inflammatory bowel disease (IBD), more precisely ulcerative colitis (UC). This work aims to study the effectiveness of daily intake of commensal lactic acid bacteria strains isolated from animal faeces, with probiotic potential effect, in different stages of chemically induced colitis in mice in order to investigate the possible mechanisms associated. For comparison will be also investigated the effects of a probiotic soy beverage - fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416 with addition of Bifidobacterium longum ATCC 15707 - and pure strains of the same probiotic microorganisms. Colitis will be induced by 3% dextran sulfate sodium (DSS), being studied two phases of colitis: acute (14 days) and chronic (28 days). The animals will then be randomly assigned into five groups (n=10): Group C: healthy animals that do not receive the microorganisms under study; Group CL: animals with colitis that do not receive the microorganisms under study; Group CLC: animals with colitis that receive a mixture of probiotics strains (E. faecium CRL 183, L. helveticus 416 and B. longum ATCC 15707); Group CLF: animals with colitis that receive the probiotic beverage (E. faecium CRL 183, L. helveticus 416 e B. longum ATCC 15707). Group CLP: animals with colitis that receive the strains isolated from their own faeces (individualized treatment). The strains of lactic acid bacteria isolated from animal feces will be submitted to analysis of gastrointestinal environment resistance, antibiotic sensitivity and specie/strain identification by molecular techniques. Throughout the experimental protocol the following parameters will be monitored: disease activity index, short-chain fatty acids concentration in the faeces, and intestinal microbiota composition by independent growth techniques. At the end of each stage of colitis, the animals will be euthanized and the large intestine will be removed to perform histological and immunohistochemistry analysis in the colon, to determine the concentration of cytokines (IL-1², IL-6, IL-10, IL12, TGF- ² e TNF-±), biochemistry markers (MPO activity, MDA and NO) and protein expression (ZO1, claudin 1, 2 e 3 and occludin). (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CELIBERTO, LARISSA S.; PINTO, ROSELI APARECIDA; ROSSI, ELIZEU ANTONIO; VALLANCE, BRUCE A.; CAVALLINI, DANIELA C. U.. Isolation and Characterization of Potentially Probiotic Bacterial Strains from Mice: Proof of Concept for Personalized Probiotics. NUTRIENTS, v. 10, n. 11, NOV 2018. (14/15129-1, 14/15130-0, 15/21958-3)